SG11202003743SA - Compounds as mpges-1 inhibitors - Google Patents
Compounds as mpges-1 inhibitorsInfo
- Publication number
- SG11202003743SA SG11202003743SA SG11202003743SA SG11202003743SA SG11202003743SA SG 11202003743S A SG11202003743S A SG 11202003743SA SG 11202003743S A SG11202003743S A SG 11202003743SA SG 11202003743S A SG11202003743S A SG 11202003743SA SG 11202003743S A SG11202003743S A SG 11202003743SA
- Authority
- SG
- Singapore
- Prior art keywords
- mpges
- inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203033 | 2017-11-22 | ||
| PCT/EP2018/082146 WO2019101826A1 (en) | 2017-11-22 | 2018-11-22 | Compounds as mpges-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003743SA true SG11202003743SA (en) | 2020-06-29 |
Family
ID=60450482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003743SA SG11202003743SA (en) | 2017-11-22 | 2018-11-22 | Compounds as mpges-1 inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11672787B2 (en) |
| EP (1) | EP3713564B1 (en) |
| JP (2) | JP2021504307A (en) |
| KR (1) | KR20200090818A (en) |
| CN (1) | CN111417393A (en) |
| AU (1) | AU2018371153B2 (en) |
| BR (1) | BR112020010089A2 (en) |
| CA (1) | CA3079483A1 (en) |
| ES (1) | ES2963906T3 (en) |
| IL (1) | IL274821A (en) |
| MX (1) | MX2020005238A (en) |
| PL (1) | PL3713564T3 (en) |
| SG (1) | SG11202003743SA (en) |
| WO (1) | WO2019101826A1 (en) |
| ZA (1) | ZA202002103B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4241842A3 (en) * | 2017-04-05 | 2023-11-08 | Khondrion Ip B.V. | Novel treatment of mitochondrial diseases |
| NL2024431B1 (en) * | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02250831A (en) | 1989-03-23 | 1990-10-08 | Kuraray Co Ltd | 3,4-dihydro-2h-benzopyran derivative and anti-peptic ulcer agent containing thereof as active ingredient |
| EP1828143B1 (en) | 2004-12-17 | 2013-03-20 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
| US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
| DE102006053475A1 (en) | 2006-11-14 | 2008-06-19 | Eberhard-Karls-Universität Tübingen | Preparations for the inhibition of prostaglandin E2 synthesis |
| DE102006058450A1 (en) | 2006-12-12 | 2008-06-19 | Eberhard-Karls-Universität Tübingen | Preparations for the inhibition of prostaglandin E2 synthesis |
| EA038941B1 (en) * | 2007-11-06 | 2021-11-12 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
| WO2009130242A1 (en) | 2008-04-23 | 2009-10-29 | Novasaid Ab | Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases |
| DE102008027331A1 (en) | 2008-06-07 | 2009-12-10 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Use of indole-3-carboxylic acid esters for the inhibition of microsomal prostaglandin E2 synthase |
| UY32138A (en) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | SUBSTITUTED AMIDES 2- (2,6-DICLORO-PHENYLAMINE) -6-FLUORO-1-METHYL-1H-BENCIMIDAZOL-5-CARBOXYL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
| UY32470A (en) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | DERIVATIVES OF 2- {2-CHLORINE-5 - [(REPLACED) METHYL] PHENYLAMINE} -1-METHYL] PHENYLAMINE} -1-METHYLBENCIMIDAZOL-5-CARBOXAMIDES-N- (SUBSTITUTED) AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS, COMPOSITIONS AND APPLIANCE |
| WO2010127152A2 (en) | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
| WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| TW201305178A (en) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | Tricyclic compounds as mPGES-1 inhibitors |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| WO2012110860A1 (en) | 2011-02-17 | 2012-08-23 | Glenmark Pharmaceuticals S.A. | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2013038308A1 (en) | 2011-09-15 | 2013-03-21 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2013072825A1 (en) | 2011-11-16 | 2013-05-23 | Glenmark Pharmaceuticals S.A. | Phtalazinone derivatives as mpegs -1 inhibitors |
| US9006257B2 (en) | 2012-02-09 | 2015-04-14 | Glenmark Pharmaceuticals S.A. | Bicyclic compounds as mPGES-1 inhibitors |
| WO2013153535A1 (en) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| SI2872497T2 (en) * | 2012-07-12 | 2019-12-31 | Khondrion Ip B.V. | Chromanyl derivatives for treating mitochondrial disease |
| US9388156B2 (en) * | 2012-07-12 | 2016-07-12 | Khondiron IP B.V. | Chromanyl derivatives for treating mitochondrial disease |
| NL2010010C2 (en) | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| CN105636951B (en) | 2014-04-14 | 2018-05-15 | 上海恒瑞医药有限公司 | Amide derivatives and its officinal salt, its preparation method and its application in medicine |
| NL2013012B1 (en) * | 2014-06-17 | 2016-07-05 | Sulfateq Bv | Compounds for the treatment of chronic obstructive airway diseases. |
| BR112017024854B1 (en) | 2015-05-22 | 2023-12-26 | Sulfateq B.V | Use of a compound |
| US10815211B2 (en) * | 2015-10-08 | 2020-10-27 | Khondrion Ip B.V. | Compounds for treating mitochondrial disease |
| EP4241842A3 (en) * | 2017-04-05 | 2023-11-08 | Khondrion Ip B.V. | Novel treatment of mitochondrial diseases |
| WO2019101825A1 (en) * | 2017-11-22 | 2019-05-31 | Khondrion Ip B.V. | Novel compounds for use in treating depression and migraine |
-
2018
- 2018-11-22 MX MX2020005238A patent/MX2020005238A/en unknown
- 2018-11-22 SG SG11202003743SA patent/SG11202003743SA/en unknown
- 2018-11-22 KR KR1020207017202A patent/KR20200090818A/en active Search and Examination
- 2018-11-22 CA CA3079483A patent/CA3079483A1/en active Pending
- 2018-11-22 ES ES18808288T patent/ES2963906T3/en active Active
- 2018-11-22 PL PL18808288.7T patent/PL3713564T3/en unknown
- 2018-11-22 JP JP2020526121A patent/JP2021504307A/en active Pending
- 2018-11-22 EP EP18808288.7A patent/EP3713564B1/en active Active
- 2018-11-22 WO PCT/EP2018/082146 patent/WO2019101826A1/en unknown
- 2018-11-22 BR BR112020010089-7A patent/BR112020010089A2/en unknown
- 2018-11-22 AU AU2018371153A patent/AU2018371153B2/en active Active
- 2018-11-22 CN CN201880075549.3A patent/CN111417393A/en active Pending
- 2018-11-22 US US16/765,169 patent/US11672787B2/en active Active
-
2020
- 2020-05-04 ZA ZA2020/02103A patent/ZA202002103B/en unknown
- 2020-05-20 IL IL274821A patent/IL274821A/en unknown
-
2023
- 2023-09-11 JP JP2023147032A patent/JP2024009799A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200345706A1 (en) | 2020-11-05 |
| WO2019101826A1 (en) | 2019-05-31 |
| ES2963906T3 (en) | 2024-04-03 |
| CA3079483A1 (en) | 2019-05-31 |
| AU2018371153B2 (en) | 2023-07-13 |
| EP3713564B1 (en) | 2023-11-15 |
| JP2024009799A (en) | 2024-01-23 |
| KR20200090818A (en) | 2020-07-29 |
| PL3713564T3 (en) | 2024-04-08 |
| RU2020120235A (en) | 2021-12-22 |
| AU2018371153A1 (en) | 2020-06-04 |
| CN111417393A (en) | 2020-07-14 |
| BR112020010089A2 (en) | 2020-11-03 |
| JP2021504307A (en) | 2021-02-15 |
| EP3713564A1 (en) | 2020-09-30 |
| EP3713564C0 (en) | 2023-11-15 |
| MX2020005238A (en) | 2020-08-24 |
| US11672787B2 (en) | 2023-06-13 |
| ZA202002103B (en) | 2023-12-20 |
| IL274821A (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3371190T1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
| GB201704327D0 (en) | Compounds | |
| GB201700814D0 (en) | Compounds | |
| LT3609898T (en) | Compounds useful as ret inhibitors | |
| GB201704325D0 (en) | Compounds | |
| EP3660003C0 (en) | Heterocyclic compound | |
| EP3693368C0 (en) | Heterocyclic compound | |
| IL274821A (en) | Compounds as mpges-1 inhibitors | |
| GB201707938D0 (en) | Compounds | |
| GB201706162D0 (en) | Compounds | |
| PT3643718T (en) | Heterocyclic compound | |
| GB201707856D0 (en) | Compounds | |
| GB201702221D0 (en) | Compounds | |
| ZA201907792B (en) | Heterocyclic compound | |
| GB201707852D0 (en) | Compounds | |
| GB201703282D0 (en) | Compounds | |
| ZA201907793B (en) | Heterocyclic compound | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201708507D0 (en) | Inhibitor compounds | |
| GB201708510D0 (en) | Inhibitor compounds | |
| GB201708502D0 (en) | Inhibitor compounds | |
| GB201705968D0 (en) | Inhibitor compounds | |
| GB201707917D0 (en) | Compounds | |
| GB201706311D0 (en) | Compounds | |
| GB201706299D0 (en) | Compounds |